Literature DB >> 26616633

Oseltamivir for influenza infection in children: risks and benefits.

Susanna Esposito1, Nicola Principi1.   

Abstract

Influenza is a common disease affecting many children each year. In a number of cases, particularly in children <2 years old and in those with severe chronic underlying disease, influenza can be complicated by lower respiratory tract infections, acute otitis media, rhinosinusitis, febrile seizures, dehydration or encephalopathy. Oseltamivir is the influenza virus drug that is most commonly studied in children for both the treatment and prevention of influenza. To avoid the risk that children with mild influenza or patients suffering from different viral infections receive oseltamivir, oseltamivir treatment should be recommended only in severe influenza cases, especially if confirmed by reliable laboratory tests. However, therapy must be initiated considering the risk of complications and the presence of severe clinical manifestations at age- and weight-appropriate doses. Because the vaccine remains the best option for preventing influenza and its complications, prophylaxis using oseltamivir should only be considered in select patients.

Entities:  

Keywords:  Antiviral prophylaxis; antiviral therapy; children; influenza; neuraminidase inhibitor; oseltamivir

Mesh:

Substances:

Year:  2015        PMID: 26616633     DOI: 10.1586/17476348.2016.1126182

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  5 in total

1.  Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children.

Authors:  Jianru Qin; Jilei Lin; Xiangfei Zhang; Shuhua Yuan; Chiyu Zhang; Yong Yin
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

2.  The Hypothiocyanite and Amantadine Combination Treatment Prevents Lethal Influenza A Virus Infection in Mice.

Authors:  Nuha Milad Ashtiwi; Demba Sarr; Tamás Nagy; Z Beau Reneer; Ralph A Tripp; Balázs Rada
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

3.  A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.

Authors:  Ali A Nasrallah; Sarah H Farran; Zainab A Nasrallah; Mohamad A Chahrour; Hamza A Salhab; Mohamad Y Fares; Hussein H Khachfe; Elie A Akl
Journal:  J Clin Epidemiol       Date:  2020-06-08       Impact factor: 6.437

Review 4.  Drugs for Influenza Treatment: Is There Significant News?

Authors:  Nicola Principi; Barbara Camilloni; Anna Alunno; Ilaria Polinori; Alberto Argentiero; Susanna Esposito
Journal:  Front Med (Lausanne)       Date:  2019-05-28

Review 5.  Antiviral Drugs in Influenza.

Authors:  Magdalena Świerczyńska; Dagmara M Mirowska-Guzel; Edyta Pindelska
Journal:  Int J Environ Res Public Health       Date:  2022-03-04       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.